Cargando…

CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment

Photodynamic therapy (PDT) offers localized focal ablation in unresectable pancreatic tumors while tissues surrounding the treatment volume experience a lower light dose, termed photodynamic priming (PDP). While PDP does not cause tissue damage, it has been demonstrated to promote vascular permeabil...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincent, Phuong, Maeder, Matthew E, Hunt, Brady, Linn, Bryan, Mangels-Dick, Tiffany, Hasan, Tayyaba, Wang, Kenneth K, Pogue, Brian W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322215/
https://www.ncbi.nlm.nih.gov/pubmed/34261044
http://dx.doi.org/10.1088/1361-6560/ac1458
_version_ 1785068703459573760
author Vincent, Phuong
Maeder, Matthew E
Hunt, Brady
Linn, Bryan
Mangels-Dick, Tiffany
Hasan, Tayyaba
Wang, Kenneth K
Pogue, Brian W
author_facet Vincent, Phuong
Maeder, Matthew E
Hunt, Brady
Linn, Bryan
Mangels-Dick, Tiffany
Hasan, Tayyaba
Wang, Kenneth K
Pogue, Brian W
author_sort Vincent, Phuong
collection PubMed
description Photodynamic therapy (PDT) offers localized focal ablation in unresectable pancreatic tumors while tissues surrounding the treatment volume experience a lower light dose, termed photodynamic priming (PDP). While PDP does not cause tissue damage, it has been demonstrated to promote vascular permeability, improve drug delivery, alleviate tumor cell density, and reduce desmoplasia and the resultant internal pressure in pre-clinical evaluation. Preclinical data supports PDP as a neoadjuvant therapy beneficial to subsequent chemotherapy or immunotherapy, yet it is challenging to quantify PDP effects in clinical treatment without additional imaging and testing. This study investigated the potential of radiomic analysis using CT scans acquired before and after PDT to identify areas experiencing PDT-induced necrosis as well as quantify PDP effects in the surrounding tissues. A total of 235 CT tumor slices from seven patients undergoing PDT for pancreatic tumors were examined. Radiomic features assessed included intensity metrics (CT number in Hounsfield Units) and texture analysis using several gray-level co-occurrence matrix (GLCM) parameters. Pre-treatment scans of tumor areas that resulted in PDT-induced necrosis showed statistically significant differences in intensity and texture-based features that could be used to predict the regions that did respond (paired t-test, response versus no response, p < 0.001). Evaluation of PDP effects on the surrounding tissues also demonstrated statistically significant differences, in tumor mean value, standard deviation, and GLCM parameters of contrast, dissimilarity and homogeneity (t-test, pre versus post, p < 0.001). Using leave-one-out cross validation, six intensity and texture-based features were combined into a support-vector machine model which demonstrated reliable prediction of treatment effects for six out of seven patients (ROC curve, AUC = 0.93). This study provides pilot evidence that texture features extracted from CT scans could be utilized as an effective clinical diagnostic prediction and assessment of PDT and PDP effects in pancreatic tumors. (clinical trial NCT03033225)
format Online
Article
Text
id pubmed-10322215
institution National Center for Biotechnology Information
language English
publishDate 2021
record_format MEDLINE/PubMed
spelling pubmed-103222152023-07-05 CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment Vincent, Phuong Maeder, Matthew E Hunt, Brady Linn, Bryan Mangels-Dick, Tiffany Hasan, Tayyaba Wang, Kenneth K Pogue, Brian W Phys Med Biol Article Photodynamic therapy (PDT) offers localized focal ablation in unresectable pancreatic tumors while tissues surrounding the treatment volume experience a lower light dose, termed photodynamic priming (PDP). While PDP does not cause tissue damage, it has been demonstrated to promote vascular permeability, improve drug delivery, alleviate tumor cell density, and reduce desmoplasia and the resultant internal pressure in pre-clinical evaluation. Preclinical data supports PDP as a neoadjuvant therapy beneficial to subsequent chemotherapy or immunotherapy, yet it is challenging to quantify PDP effects in clinical treatment without additional imaging and testing. This study investigated the potential of radiomic analysis using CT scans acquired before and after PDT to identify areas experiencing PDT-induced necrosis as well as quantify PDP effects in the surrounding tissues. A total of 235 CT tumor slices from seven patients undergoing PDT for pancreatic tumors were examined. Radiomic features assessed included intensity metrics (CT number in Hounsfield Units) and texture analysis using several gray-level co-occurrence matrix (GLCM) parameters. Pre-treatment scans of tumor areas that resulted in PDT-induced necrosis showed statistically significant differences in intensity and texture-based features that could be used to predict the regions that did respond (paired t-test, response versus no response, p < 0.001). Evaluation of PDP effects on the surrounding tissues also demonstrated statistically significant differences, in tumor mean value, standard deviation, and GLCM parameters of contrast, dissimilarity and homogeneity (t-test, pre versus post, p < 0.001). Using leave-one-out cross validation, six intensity and texture-based features were combined into a support-vector machine model which demonstrated reliable prediction of treatment effects for six out of seven patients (ROC curve, AUC = 0.93). This study provides pilot evidence that texture features extracted from CT scans could be utilized as an effective clinical diagnostic prediction and assessment of PDT and PDP effects in pancreatic tumors. (clinical trial NCT03033225) 2021-08-23 /pmc/articles/PMC10322215/ /pubmed/34261044 http://dx.doi.org/10.1088/1361-6560/ac1458 Text en https://creativecommons.org/licenses/by/4.0/Original content from this work may be used under the terms of the Creative Commons Attribution 4.0 licence (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Vincent, Phuong
Maeder, Matthew E
Hunt, Brady
Linn, Bryan
Mangels-Dick, Tiffany
Hasan, Tayyaba
Wang, Kenneth K
Pogue, Brian W
CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment
title CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment
title_full CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment
title_fullStr CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment
title_full_unstemmed CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment
title_short CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment
title_sort ct radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322215/
https://www.ncbi.nlm.nih.gov/pubmed/34261044
http://dx.doi.org/10.1088/1361-6560/ac1458
work_keys_str_mv AT vincentphuong ctradiomicfeaturesofphotodynamicpriminginclinicalpancreaticadenocarcinomatreatment
AT maedermatthewe ctradiomicfeaturesofphotodynamicpriminginclinicalpancreaticadenocarcinomatreatment
AT huntbrady ctradiomicfeaturesofphotodynamicpriminginclinicalpancreaticadenocarcinomatreatment
AT linnbryan ctradiomicfeaturesofphotodynamicpriminginclinicalpancreaticadenocarcinomatreatment
AT mangelsdicktiffany ctradiomicfeaturesofphotodynamicpriminginclinicalpancreaticadenocarcinomatreatment
AT hasantayyaba ctradiomicfeaturesofphotodynamicpriminginclinicalpancreaticadenocarcinomatreatment
AT wangkennethk ctradiomicfeaturesofphotodynamicpriminginclinicalpancreaticadenocarcinomatreatment
AT poguebrianw ctradiomicfeaturesofphotodynamicpriminginclinicalpancreaticadenocarcinomatreatment